<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30212">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02043717</url>
  </required_header>
  <id_info>
    <org_study_id>vitaminD-HMO-CTIL</org_study_id>
    <nct_id>NCT02043717</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D on Lung Function in Patients With Cystic Fibrosis</brief_title>
  <official_title>The Effect of Vitamin D on Lung Function in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators study is designed to test the hypothesis that correction of vitamin D in
      CF patients can increase their lung function and decrease the number of their pulmonary
      exacerbations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D deficiency is a known problem in CF patients.  The CF Foundation Committee
      published in April 2012 new guidelines for administering vitamin D in CF patients.  The
      investigators' study is designed to look for association between normal serum vitamin D
      levels and lung function.  ~100 CF patients from The Center of Chronic Diseases in Hadassah
      Medical Organization will be treated according to the new guidelines, and their lung
      function will be tested once a month during the trial, which will be held for at least one
      year.  In this study, the investigators' goal is to test the efficiency of the new
      guidelines in correcting serum vitamin D levels, and to follow other related factors such as
      growth indices (height, weight, BMI), bone mineral density, number of pulmonary
      exacerbations and number of hospital admissions.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>FEV1 (by % of predicted)</measure>
    <time_frame>Baseline, and then, on average, once a month during trial (at least one year).</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary exacerbations</measure>
    <time_frame>number in a year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions</measure>
    <time_frame>number in a year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Vitamin D level</measure>
    <time_frame>Baseline, and then, on average, once a month during trial (at least one year).</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess correction efficiency and hypervitaminosis D</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF patients</arm_group_label>
    <description>Both children and adults, with or without vitamin D deficiency.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>According to the new guidelines by:
Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism [Internet]. 2012 May [cited 2012 Oct 31];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505</description>
    <arm_group_label>CF patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CF patients (both children and adults) from The Center for Chronic Diseases in Hadassah
        Medical Organization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and laboratory diagnosis of Cystic Fibrosis

        Exclusion Criteria:

          -  Age under 4 years old (because of the inability to assess lung function in a reliable
             fashion)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wilschanski, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Wilschanski, Prof.</last_name>
    <phone>00 9722-5845039</phone>
    <email>michaelwil@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lemberg, PhD</last_name>
    <phone>00 972 2 6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Wilschanski, Prof.</last_name>
      <phone>00 9722-5845039</phone>
      <email>michaelwil@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Wilschanski, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasmeen Abu-Fraiha, B.Med.Sci</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, Marshall BC, Borowitz D; Cystic Fibrosis Foundation Vitamin D Evidence-Based Review Committee. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012 Apr;97(4):1082-93. doi: 10.1210/jc.2011-3050. Epub 2012 Mar 7.</citation>
    <PMID>22399505</PMID>
  </reference>
  <reference>
    <citation>Green D, Carson K, Leonard A, Davis JE, Rosenstein B, Zeitlin P, Mogayzel P Jr. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr. 2008 Oct;153(4):554-9. Epub 2008 Jun 27.</citation>
    <PMID>18589445</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>January 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Lung function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
